Retour à la liste des essais cliniquesENT/Head and Neck Cancers

SURVEILLE HPV

National, multicentre, open-label, randomised, phase II study evaluating HPV circulating DNA as biomarker to detect the recurrence, in order to improve post therapeutic surveillance of HPV-driven oropharyngeal cancers.

Ouvert à Paris depuis le : 08/01/2025
Ouvert à Saint-Cloud depuis le : 01/11/2024
Public cible : Adult
Phase : Phase II

Description de l'essai

Evaluate the negative predictive value (NPV) of circulating HPV DNA (HPVctDNA) at 2 years for detecting recurrence of oropharyngeal cancer (OPC) in patients in complete remission after treatment. The goal is to determine whether the detection of circulating HPV DNA can be used to predict the absence of cancer recurrence.;Improve post-therapeutic surveillance of patients with HPV-driven oropharyngeal cancers by using this circulating DNA as a biomarker to detect early recurrence, enabling faster and more targeted management of the disease.

Url of the trial

Investigateur principal

JOEY MARTIN

Médecin

Contacter